Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/-, exclusive for Moneycontrol Pro subscribers. Register now!

Sun Pharma joins biosimilars race, to target assets with patent expiries in 7-10 years

Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on R&D.

May 28, 2021 / 04:08 PM IST
File image

File image

  • bselive
  • nselive
Todays L/H

Sun Pharma, India's largest drug maker, said it will be joining the race to develop biosimilar drugs.

"We are evaluating development of some biosimilars, which can be classified amongst the third wave," said Dilip Shanghvi, Managing Director, at the company's earnings call on May 27.

"I think we are looking at products, which have significant future patent expiry dates, we can be amongst the first approvals. That's the focus ... we are finding a way to leverage our presence in the that we can successfully build a biosimilars portfolio," he said.

Shanghvi anticipates a timeline of 2028-2030 for the proposed biosimilar assets to hit the market.

He added that Sun Pharma would develop biosimilars within the limits of usual R&D (research and development) and capital expenditure budgets. Sun Pharma targets to spend between 8 and 9 percent of turnover on research and development (R&D).


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Sun Pharma had sales of Rs. 33,139.2 crore in FY21.

"It shouldn't be a big drain on our cash flows," Shanghvi said.

Late entrant

Sun Pharma chief Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars saying that it's not a category that he understands.

Biosimilar are copies of biologic drugs, but companies developing them will have to conduct clinical trials to establish similarity with the original biologic drug.

The manufacturing is also complex as it involves possessing biotechnology capabilities.

The global biosimilars market size is projected to reach $35.7 billion by 2025 from $11.8 billion in 2020, at a CAGR (Compound Annual Growth Rate) of 24.7 percent, according to

But the competition is hotting up with several Indian drug makers like Biocon, Dr Reddy's, Lupin, Aurobindo and Cadila Healthcare, among others, aiming to get a slice of the market.

Shanghvi statements indicate that Sun Pharma is in it for the long haul.

But being a late entrant, did Sun Pharma miss the early mover advantage?

"I am expecting that over time, with familiarity and confidence that doctors will develop on biosimilars, we will see an increasing percentage of patients being treated with biosimilars," Shanghvi said.

Experts concur with Shanghvi's view.

"I don't perceive late entry as a disadvantage. Especially in the context of how biosimilar markets have evolved over the last few years, regulatory impetus has been high," said Pushpa Vijayaraghavan, Director & Practice Lead - Healthcare at Sathguru Management Consultants.

Vijayaraghavan advises companies on biosimilars and vaccine strategy.

"Commercial opportunity in the largest market in the United States is just opening up. If the portfolio is well conceived and targets mature markets where opportunity for return on investment is now ripe, the foray into biosimilars could be a good call," he said.

Another analyst at a Mumbai-based brokerage house tracking Sun Pharma who didn't want to be named, said the company has the regulatory, and clinical expertise to develop biosimilars, targeting highly regulated markets.

"It has already developed and launched specialty products; biosimilars aren't going to be much different. Coming late also helps because they don't have to repeat the mistakes some early mover companies had made at regulatory, manufacturing and commercialisation stages," the analyst said.

Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: May 28, 2021 04:08 pm
ISO 27001 - BSI Assurance Mark